Skip to main content
SpringerLink
Log in

Managing Frontal Sinusitis from Systemic Inflammatory Disease

  • Chapter
  • First Online:
Frontal Sinus Surgery

  • 618 Accesses

Abstract

In this chapter, we outline the systemic diseases that can be encountered in patients with chronic frontal sinusitis, starting with identification of clinical patterns. Next, we compare and contrast the various conditions that may be associated with chronic frontal sinusitis, including allergic fungal sinusitis, aspirin-exacerbated respiratory disease, common variable immune deficiency, eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, HIV, IgG4-related disease, odontogenic sinusitis, cystic fibrosis, primary ciliary dyskinesia, sarcoidosis, and cocaine-induced midline destructive lesions. We discuss examination features as well as laboratory and radiographic findings. Finally, we review in detail the management options specific to the identified systemic diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ACE:

Angiotensin-converting enzyme

ACR:

American College of Rheumatology

AERD:

Aspirin-exacerbated respiratory disease

AFS:

Allergic fungal sinusitis

ANCA:

Anti-neutrophil cytoplasmic antibody

Anti-MPO ab:

Anti-myeloperoxidase antibody

Anti-PR3 ab:

Anti-proteinase 3 antibody

BVAS:

Birmingham Vasculitis Activity Score

BVAS/WG:

BVAS for Wegener’s granulomatosis (GPA)

C-ANCA:

Cytoplasmic anti-neutrophil cytoplasmic antibody

CF:

Cystic fibrosis

CHCC:

Chapel Hill Consensus Conference

CIMDL:

Cocaine-induced midline destructive lesions syndrome

CRP:

C-reactive protein

CRS:

Chronic rhinosinusitis

CRSsNP:

Chronic rhinosinusitis without (sans) nasal polyps

CRSwNP:

Chronic rhinosinusitis with nasal polyps

CVID:

Common variable immune deficiency

EGPA:

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)

EMA:

European Medical Agency

ENT:

Ear, nose, and throat

ESR:

Erythrocyte sedimentation rate

EULAR:

European League Against Rheumatism

GPA:

Granulomatosis with polyangiitis (Wegener’s granulomatosis)

HEENT:

Head, eye, ear, nose, and throat

HIV:

Human immunodeficiency virus

Ig:

Immunoglobulin

IgG4-RD:

IgG4-related disease

MPA:

Microscopic polyangiitis

P-ANCA:

Perinuclear anti-neutrophil cytoplasmic antibody

PCD:

Primary ciliary dyskinesia

TMP/SMX:

Trimethoprim/sulfamethoxazole

VDI:

Vasculitis damage index

References

  1. Rank MA, Hoxworth JM, Lal D. Sorting out “sinus headache”. J Allergy Clin Immunol Pract. 2016;4(5):1013–4.

    Article  Google Scholar 

  2. Snidvongs K, McLachlan R, Sacks R, Earls P, Harvey RJ. Correlation of the Kennedy Osteitis Score to clinico-histologic features of chronic rhinosinusitis. Int Forum Allergy Rhinol. 2013;3(5):369–75.

    Article  PubMed  Google Scholar 

  3. Pearce FA, Lanyon PC, Grainge MJ, Shaunak R, Mahr A, Hubbard RB, et al. Incidence of ANCA-associated vasculitis in a UK mixed ethnicity population. Rheumatology (Oxford). 2016;55(9):1656–63.

    Article  Google Scholar 

  4. Mahr A, Guillevin L, Poissonnet M, Ayme S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 2004;51(1):92–9.

    Article  PubMed  Google Scholar 

  5. Baughman RP, Field S, Costabel U, Crystal RG, Culver DA, Drent M, et al. Sarcoidosis in America. Analysis based on health care use. Ann Am Thorac Soc. 2016;13(8):1244–52.

    Article  PubMed  Google Scholar 

  6. Ungprasert P, Carmona EM, Crowson CS, Matteson EL. Diagnostic utility of angiotensin-converting enzyme in sarcoidosis: a population-based study. Lung. 2016;194(1):91–5.

    Article  CAS  PubMed  Google Scholar 

  7. Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22(1):21–30.

    Article  CAS  PubMed  Google Scholar 

  8. Watts RA, Mahr A, Mohammad AJ, Gatenby P, Basu N, Flores-Suarez LF. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Nephrol Dial Transplant. 2015;30(Suppl 1):i14–22.

    Article  CAS  PubMed  Google Scholar 

  9. Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine. 1984;63(2):65–81.

    Article  CAS  PubMed  Google Scholar 

  10. Sinico RA, Di Toma L, Maggiore U, Tosoni C, Bottero P, Sabadini E, et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis. 2006;47(5):770–9.

    Article  PubMed  Google Scholar 

  11. Chaigne B, Terrier B, Thieblemont N, Witko-Sarsat V, Mouthon L. Dividing the Janus vasculitis? Pathophysiology of eosinophilic granulomatosis with polyangiitis. Autoimmun Rev. 2016;15(2):139–45.

    Article  CAS  PubMed  Google Scholar 

  12. Ueki S, Tokunaga T, Fujieda S, Honda K, Hirokawa M, Spencer LA, et al. Eosinophil ETosis and DNA traps: a new look at eosinophilic inflammation. Curr Allergy Asthma Rep. 2016;16(8):54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Khoury P, Grayson PC, Klion AD. Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat Rev Rheumatol. 2014;10(8):474–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68(12):1827–32.

    Article  CAS  PubMed  Google Scholar 

  15. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40(2):371–80.

    Article  CAS  PubMed  Google Scholar 

  16. Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al. A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum. 2001;44(4):912–20.

    Article  CAS  PubMed  Google Scholar 

  17. Bacciu A, Bacciu S, Mercante G, Ingegnoli F, Grasselli C, Vaglio A, et al. Ear, nose and throat manifestations of Churg-Strauss syndrome. Acta Otolaryngol. 2006;126(5):503–9.

    Article  PubMed  Google Scholar 

  18. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine. 1996;75(1):17–28.

    Article  CAS  PubMed  Google Scholar 

  19. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine. 2011;90(1):19–27.

    Article  PubMed  Google Scholar 

  20. Moosig F, Bremer JP, Hellmich B, Holle JU, Holl-Ulrich K, Laudien M, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis. 2013;72(6):1011–7.

    Article  PubMed  Google Scholar 

  21. Comarmond C, Pagnoux C, Khellaf M, Cordier JF, Hamidou M, Viallard JF, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;65(1):270–81.

    Article  PubMed  Google Scholar 

  22. Durel CA, Berthiller J, Caboni S, Jayne D, Ninet J, Hot A. Long-term followup of a multicenter cohort of 101 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Arthritis Care Res. 2016;68(3):374–87.

    Article  Google Scholar 

  23. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488–98.

    Article  CAS  PubMed  Google Scholar 

  24. Villa-Forte A, Clark TM, Gomes M, Carey J, Mascha E, Karafa MT, et al. Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience. Medicine. 2007;86(5):269–77.

    Article  CAS  PubMed  Google Scholar 

  25. DeRemee RA. The treatment of Wegener’s granulomatosis with trimethoprim/sulfamethoxazole: illusion or vision? Arthritis Rheum. 1988;31(8):1068–74.

    Article  CAS  PubMed  Google Scholar 

  26. Leavitt RY, Hoffman GS, Fauci AS. The role of trimethoprim/sulfamethoxazole in the treatment of Wegener’s granulomatosis. Arthritis Rheum. 1988;31(8):1073–4.

    Article  CAS  PubMed  Google Scholar 

  27. Rasmussen N, Petersen J, Remvig L, Andersen V. Treatment of Wegener’s granulomatosis with trimethoprim-sulfamethoxazole. APMIS Suppl. 1990;19:61–2.

    Article  CAS  PubMed  Google Scholar 

  28. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med. 1994;120(1):12–7.

    Article  CAS  PubMed  Google Scholar 

  29. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996;335(1):16–20.

    Article  CAS  PubMed  Google Scholar 

  30. Laudien M, Gadola SD, Podschun R, Hedderich J, Paulsen J, Reinhold-Keller E, et al. Nasal carriage of Staphylococcus aureus and endonasal activity in Wegener s granulomatosis as compared to rheumatoid arthritis and chronic rhinosinusitis with nasal polyps. Clin Exp Rheumatol. 2010;28(1 Suppl 57):51–5.

    PubMed  Google Scholar 

  31. Popa ER, Stegeman CA, Abdulahad WH, van der Meer B, Arends J, Manson WM, et al. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener’s granulomatosis. Rheumatology. 2007;46(6):1029–33.

    Article  CAS  PubMed  Google Scholar 

  32. Lepse N, Abdulahad WH, Kallenberg CG, Heeringa P. Immune regulatory mechanisms in ANCA-associated vasculitides. Autoimmun Rev. 2011;11(2):77–83.

    Article  CAS  PubMed  Google Scholar 

  33. Glasner C, van Timmeren MM, Stobernack T, Omansen TF, Raangs EC, Rossen JW, et al. Low anti-staphylococcal IgG responses in granulomatosis with polyangiitis patients despite long-term Staphylococcus aureus exposure. Sci Rep. 2015;5:8188.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Laudien M, Hasler R, Wohlers J, Bock J, Lipinski S, Bremer L, et al. Molecular signatures of a disturbed nasal barrier function in the primary tissue of Wegener’s granulomatosis. Mucosal Immunol. 2011;4(5):564–73.

    Article  CAS  PubMed  Google Scholar 

  35. de Groot K, Reinhold-Keller E, Tatsis E, Paulsen J, Heller M, Nolle B, et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener’s granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum. 1996;39(12):2052–61.

    Article  PubMed  Google Scholar 

  36. Kallenberg CG. Pathogenesis and treatment of ANCA-associated vasculitides. Clin Exp Rheumatol. 2015;33(4 Suppl 92):S11–4.

    PubMed  Google Scholar 

  37. Cornec D, Cornec-Le Gall E, Fervenza FC, Specks U. ANCA-associated vasculitis – clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol. 2016;12(10):570–9.

    Article  CAS  PubMed  Google Scholar 

  38. Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583–94.

    Article  CAS  PubMed  Google Scholar 

  39. Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Hoglund P, et al. Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015;74(1):177–84.

    Article  PubMed  Google Scholar 

  40. Aries PM, Hellmich B, Voswinkel J, Both M, Nolle B, Holl-Ulrich K, et al. Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis. 2006;65(7):853–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Holle JU, Dubrau C, Herlyn K, Heller M, Ambrosch P, Noelle B, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener’s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis. 2012;71(3):327–33.

    Article  CAS  PubMed  Google Scholar 

  42. Martinez Del Pero M, Chaudhry A, Jones RB, Sivasothy P, Jani P, Jayne D. B-cell depletion with rituximab for refractory head and neck Wegener’s granulomatosis: a cohort study. Clin Otolaryngol. 2009;34(4):328–35.

    Article  CAS  PubMed  Google Scholar 

  43. Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL. Rituximab is effective in the treatment of refractory ophthalmic Wegener’s granulomatosis. Arthritis Rheum. 2009;60(5):1540–7.

    Article  PubMed  Google Scholar 

  44. Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb Z, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15(6):623–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Surmiak M, Hubalewska-Mazgaj M, Wawrzycka-Adamczyk K, Szczeklik W, Musial J, Brzozowski T, et al. Neutrophil-related and serum biomarkers in granulomatosis with polyangiitis support extracellular traps mechanism of the disease. Clin Exp Rheumatol. 2016;34(3 Suppl 97):S98–104.

    PubMed  Google Scholar 

  46. Bligny D, Mahr A, Toumelin PL, Mouthon L, Guillevin L. Predicting mortality in systemic Wegener’s granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum. 2004;51(1):83–91.

    Article  PubMed  Google Scholar 

  47. Trimarchi M, Gregorini G, Facchetti F, Morassi ML, Manfredini C, Maroldi R, et al. Cocaine-induced midline destructive lesions: clinical, radiographic, histopathologic, and serologic features and their differentiation from Wegener granulomatosis. Medicine. 2001;80(6):391–404.

    Article  CAS  PubMed  Google Scholar 

  48. McGrath MM, Isakova T, Rennke HG, Mottola AM, Laliberte KA, Niles JL. Contaminated cocaine and antineutrophil cytoplasmic antibody-associated disease. Clin J Am Soc Nephrol. 2011;6(12):2799–805.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Trimarchi M, Sinico RA, Teggi R, Bussi M, Specks U, Meroni PL. Otorhinolaryngological manifestations in granulomatosis with polyangiitis (Wegener’s). Autoimmun Rev. 2013;12(4):501–5.

    Article  PubMed  Google Scholar 

  50. Ullrich K, Koval R, Koval E, Bapoje S, Hirsh JM. Five consecutive cases of a cutaneous vasculopathy in users of levamisole-adulterated cocaine. J Clin Rheumatol. 2011;17(4):193–6.

    Article  PubMed  Google Scholar 

  51. Govender P, Berman JS. The diagnosis of sarcoidosis. Clin Chest Med. 2015;36(4):585–602.

    Article  PubMed  Google Scholar 

  52. Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager H Jr. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(1):75–86.

    CAS  PubMed  Google Scholar 

  53. Judson MA, Baughman RP. How many organs need to be involved to diagnose sarcoidosis?: an unanswered question that, hopefully, will become irrelevant. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):6–7.

    PubMed  Google Scholar 

  54. Lazarus A. Sarcoidosis: epidemiology, etiology, pathogenesis, and genetics. Dis Mon. 2009;55(11):649–60.

    Article  PubMed  Google Scholar 

  55. Zissel G, Muller-Quernheim J. Cellular players in the immunopathogenesis of sarcoidosis. Clin Chest Med. 2015;36(4):549–60.

    Article  PubMed  Google Scholar 

  56. deShazo RD, O’Brien MM, Justice WK, Pitcock J. Diagnostic criteria for sarcoidosis of the sinuses. J Allergy Clin Immunol. 1999;103(5 Pt 1):789–95.

    Article  CAS  PubMed  Google Scholar 

  57. Inoue D, Yoshida K, Yoneda N, Ozaki K, Matsubara T, Nagai K, et al. IgG4-related disease: dataset of 235 consecutive patients. Medicine. 2015;94(15):e680.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Yamamoto M, Takahashi H. IgG4-related disease in organs other than the hepatobiliary-pancreatic system. Semin Liver Dis. 2016;36(3):274–82.

    Article  CAS  PubMed  Google Scholar 

  59. Stone JH, Brito-Zeron P, Bosch X, Ramos-Casals M. Diagnostic approach to the complexity of IgG4-related disease. Mayo Clin Proc. 2015;90(7):927–39.

    Article  CAS  PubMed  Google Scholar 

  60. Lanzillotta M, Campochiaro C, Trimarchi M, Arrigoni G, Gerevini S, Milani R, et al. Deconstructing IgG4-related disease involvement of midline structures: comparison to common mimickers. Mod Rheumatol. 2016:1–8.

    Google Scholar 

  61. Deshpande V. IgG4 related disease of the head and neck. Head Neck Pathol. 2015;9(1):24–31.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Takano K, Yamamoto M, Kondo A, Himi T. A case of reversible hyposmia associated with Mikulicz’s disease. Otolaryngol Head Neck Surg. 2009;141(3):430–1.

    Article  PubMed  Google Scholar 

  63. Takano K, Abe A, Yajima R, Kakuki T, Jitsukawa S, Nomura K, et al. Clinical evaluation of cinonasal lesions in patients with immunoglobulin G4-related disease. Ann Otol Rhinol Laryngol. 2015;124(12):965–71.

    Article  PubMed  Google Scholar 

  64. Ohno K, Matsuda Y, Arai T, Kimura Y. Nasal manifestations of IgG4-related disease: a report of two cases. Auris Nasus Larynx. 2015;42(6):483–7.

    Article  PubMed  Google Scholar 

  65. Cain RB, Colby TV, Balan V, Patel NP, Lal D. Perplexing lesions of the sinonasal cavity and skull base: IgG4-related and similar inflammatory diseases. Otolaryngol Head Neck Surg. 2014;151(3):496–502.

    Article  PubMed  Google Scholar 

  66. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6):539–51.

    Article  CAS  PubMed  Google Scholar 

  67. Peters AT, Spector S, Hsu J, Hamilos DL, Baroody FM, Chandra RK, et al. Diagnosis and management of rhinosinusitis: a practice parameter update. Ann Allergy Asthma Immunol. 2014;113(4):347–85.

    Article  PubMed  Google Scholar 

  68. Fuchs HA, Tanner SB. Granulomatous disorders of the nose and paranasal sinuses. Curr Opin Otolaryngol Head Neck Surg. 2009;17(1):23–7.

    Article  PubMed  Google Scholar 

  69. Kohanski MA, Reh DD. Chapter 11: Granulomatous diseases and chronic sinusitis. Am J Rhinol Allergy. 2013;27(Suppl 1):S39–41.

    Article  PubMed  Google Scholar 

  70. Hirsch AG, Yan XS, Sundaresan AS, Tan BK, Schleimer RP, Kern RC, et al. Five-year risk of incident disease following a diagnosis of chronic rhinosinusitis. Allergy. 2015;70(12):1613–21.

    Article  CAS  PubMed  Google Scholar 

  71. Goncalves C, Pinaffi JV, Carvalho JF, Pinna FR, Constantino GT, Voegels RL, et al. Antineutrophil cytoplasmic antibodies in chronic rhinosinusitis may be a marker of undisclosed vasculitis. Am J Rhinol. 2007;21(6):691–4.

    Article  PubMed  Google Scholar 

  72. Busaba NY, de Oliveira LV, Kieff DL. Correlation between preoperative clinical diagnosis and histopathological findings in patients with rhinosinusitis. Am J Rhinol. 2005;19(2):153–7.

    Article  PubMed  Google Scholar 

  73. Srouji IA, Andrews P, Edwards C, Lund VJ. Patterns of presentation and diagnosis of patients with Wegener’s granulomatosis: ENT aspects. J Laryngol Otol. 2007;121(7):653–8.

    Article  CAS  PubMed  Google Scholar 

  74. Sproson EL, Jones NS, Al-Deiri M, Lanyon P. Lessons learnt in the management of Wegener’s granulomatosis: long-term follow-up of 60 patients. Rhinology. 2007;45(1):63–7.

    CAS  PubMed  Google Scholar 

  75. Taylor SC, Clayburgh DR, Rosenbaum JT, Schindler JS. Progression and management of Wegener’s granulomatosis in the head and neck. Laryngoscope. 2012;122(8):1695–700.

    Article  PubMed  Google Scholar 

  76. Morgenthau AS, Teirstein AS. Sarcoidosis of the upper and lower airways. Expert Rev Respir Med. 2011;5(6):823–33.

    Article  PubMed  Google Scholar 

  77. Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(2):119–27.

    CAS  PubMed  Google Scholar 

  78. Aloulah M, Manes RP, Ng YH, Fitzgerald JE, Glazer CS, Ryan MW, et al. Sinonasal manifestations of sarcoidosis: a single institution experience with 38 cases. Int Forum Allergy Rhinol. 2013;3(7):567–72.

    Article  PubMed  Google Scholar 

  79. Zeitlin JF, Tami TA, Baughman R, Winget D. Nasal and sinus manifestations of sarcoidosis. Am J Rhinol. 2000;14(3):157–61.

    Article  CAS  PubMed  Google Scholar 

  80. Mulholland GB, Jeffery CC, Satija P, Cote DW. Immunoglobulin G4-related diseases in the head and neck: a systematic review. J Otolaryngol Head Neck Surg. 2015;44:24.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine. 1999;78(1):26–37.

    Article  CAS  PubMed  Google Scholar 

  82. Samson M, Puechal X, Devilliers H, Ribi C, Cohen P, Stern M, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun. 2013;43:60–9.

    Article  PubMed  Google Scholar 

  83. Seccia V, Fortunato S, Cristofani-Mencacci L, Dallan I, Casani AP, Latorre M, Paggiaro P, Bartoli ML, Sellari-Franceschini S, Baldini C. Focus on audiologic impairment in eosinophilic granulomatosis with polyangiitis. Laryngoscope. 2016;126(12):2792–7. https://doi.org/10.1002/lary.25964. Epub 2016 Apr 14.

  84. Cannady SB, Batra PS, Koening C, Lorenz RR, Citardi MJ, Langford C, et al. Sinonasal Wegener granulomatosis: a single-institution experience with 120 cases. Laryngoscope. 2009;119(4):757–61.

    Article  PubMed  Google Scholar 

  85. Stone JH. Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s granulomatosis etanercept trial. Arthritis Rheum. 2003;48(8):2299–309.

    Article  PubMed  Google Scholar 

  86. Trimarchi M, Bertazzoni G, Bussi M. Cocaine induced midline destructive lesions. Rhinology. 2014;52(2):104–11.

    Article  PubMed  Google Scholar 

  87. Carlson AQ, Tuot DS, Jen KY, Butcher B, Graf J, Sam R, et al. Pauci-immune glomerulonephritis in individuals with disease associated with levamisole-adulterated cocaine: a series of 4 cases. Medicine. 2014;93(17):290–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Lawson W, Jiang N, Cheng J. Sinonasal sarcoidosis: a new system of classification acting as a guide to diagnosis and treatment. Am J Rhinol Allergy. 2014;28(4):317–22.

    Article  PubMed  Google Scholar 

  89. Badhey AK, Kadakia S, Carrau RL, Iacob C, Khorsandi A. Sarcoidosis of the head and neck. Head Neck Pathol. 2015;9(2):260–8.

    Article  PubMed  Google Scholar 

  90. Culver DA. Sarcoidosis. Immunol Allergy Clin N Am. 2012;32(4):487–511.

    Article  Google Scholar 

  91. Song BH, Baiyee D, Liang J. A rare and emerging entity: sinonasal IgG4-related sclerosing disease. Allergy Rhinol (Providence). 2015;6(3):151–7.

    Article  Google Scholar 

  92. Wallace ZS, Deshpande V, Mattoo H, Mahajan VS, Kulikova M, Pillai S, et al. IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol. 2015;67(9):2466–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Petersen H, Gotz P, Both M, Hey M, Ambrosch P, Bremer JP, et al. Manifestation of eosinophilic granulomatosis with polyangiitis in head and neck. Rhinology. 2015;53(3):277–85.

    Article  PubMed  Google Scholar 

  94. Nakamaru Y, Takagi D, Suzuki M, Homma A, Morita S, Homma A, et al. Otologic and rhinologic manifestations of eosinophilic granulomatosis with polyangiitis. Audiol Neurootol. 2016;21(1):45–53.

    Article  PubMed  Google Scholar 

  95. Pakalniskis MG, Berg AD, Policeni BA, Gentry LR, Sato Y, Moritani T, et al. The many faces of granulomatosis with polyangiitis: a review of the head and neck imaging manifestations. AJR Am J Roentgenol. 2015;205(6):W619–29.

    Article  PubMed  Google Scholar 

  96. Cordier JF, Valeyre D, Guillevin L, Loire R, Brechot JM. Pulmonary Wegener’s granulomatosis. A clinical and imaging study of 77 cases. Chest. 1990;97(4):906–12.

    Article  CAS  PubMed  Google Scholar 

  97. Anderson G, Coles ET, Crane M, Douglas AC, Gibbs AR, Geddes DM, et al. Wegener’s granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. Q J Med. 1992;83(302):427–38.

    CAS  PubMed  Google Scholar 

  98. Ikeda S, Arita M, Misaki K, Kashiwagi Y, Ito Y, Yamada H, et al. Comparative investigation of respiratory tract involvement in granulomatosis with polyangiitis between PR3-ANCA positive and MPO-ANCA positive cases: a retrospective cohort study. BMC Pulm Med. 2015;15:78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Braun JJ, Imperiale A, Riehm S, Veillon F. Imaging in sinonasal sarcoidosis: CT, MRI, 67Gallium scintigraphy and 18F-FDG PET/CT features. J Neuroradiol. 2010;37(3):172–81.

    Article  PubMed  Google Scholar 

  100. Palmucci S, Torrisi SE, Caltabiano DC, Puglisi S, Lentini V, Grassedonio E, et al. Clinical and radiological features of extra-pulmonary sarcoidosis: a pictorial essay. Insights Imaging. 2016;7(4):571–87.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Oksuz MO, Werner MK, Aschoff P, Pfannenberg C. 18F-FDG PET/CT for the diagnosis of sarcoidosis in a patient with bilateral inflammatory involvement of the parotid and lacrimal glands (panda sign) and bilateral hilar and mediastinal lymphadenopathy (lambda sign). Eur J Nucl Med Mol Imaging. 2011;38(3):603.

    Article  PubMed  Google Scholar 

  102. Vaglio A, Strehl JD, Manger B, Maritati F, Alberici F, Beyer C, et al. IgG4 immune response in Churg-Strauss syndrome. Ann Rheum Dis. 2012;71(3):390–3.

    Article  CAS  PubMed  Google Scholar 

  103. Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int. 1998;53(3):743–53.

    Article  CAS  PubMed  Google Scholar 

  104. Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med. 2005;352(4):351–61.

    Article  Google Scholar 

  105. Finkielman JD, Lee AS, Hummel AM, Viss MA, Jacob GL, Homburger HA, et al. ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis. Am J Med. 2007;120(7):643.e9–14.

    Article  CAS  Google Scholar 

  106. Borner U, Landis BN, Banz Y, Villiger P, Ballinari P, Caversaccio M, et al. Diagnostic value of biopsies in identifying cytoplasmic antineutrophil cytoplasmic antibody-negative localized Wegener’s granulomatosis presenting primarily with sinonasal disease. Am J Rhinol Allergy. 2012;26(6):475–80.

    Article  PubMed  Google Scholar 

  107. Del Buono EA, Flint A. Diagnostic usefulness of nasal biopsy in Wegener’s granulomatosis. Hum Pathol. 1991;22(2):107–10.

    Article  PubMed  Google Scholar 

  108. Devaney KO, Travis WD, Hoffman G, Leavitt R, Lebovics R, Fauci AS. Interpretation of head and neck biopsies in Wegener’s granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol. 1990;14(6):555–64.

    Article  CAS  PubMed  Google Scholar 

  109. Chang SY, Keogh KA, Lewis JE, Ryu JH, Cornell LD, Garrity JA, et al. IgG4-positive plasma cells in granulomatosis with polyangiitis (Wegener’s): a clinicopathologic and immunohistochemical study on 43 granulomatosis with polyangiitis and 20 control cases. Hum Pathol. 2013;44(11):2432–7.

    Article  CAS  PubMed  Google Scholar 

  110. Wiesner O, Russell KA, Lee AS, Jenne DE, Trimarchi M, Gregorini G, et al. Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum. 2004;50(9):2954–65.

    Article  CAS  PubMed  Google Scholar 

  111. Consensus conference: activity of sarcoidosis. Third WASOG meeting, Los Angeles, USA, September 8-11, 1993. Eur Respir J. 1994;7(3):624–7.

    Google Scholar 

  112. Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181–92.

    Article  PubMed  Google Scholar 

  113. Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet. 2015;385(9976):1460–71.

    Article  CAS  PubMed  Google Scholar 

  114. Akiyama M, Kaneko Y, Hayashi Y, Takeuchi T. IgG4-related disease involving vital organs diagnosed with lip biopsy: a case report and literature review. Medicine. 2016;95(24):e3970.

    Article  PubMed  PubMed Central  Google Scholar 

  115. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.

    Article  CAS  PubMed  Google Scholar 

  116. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094–100.

    Article  CAS  PubMed  Google Scholar 

  117. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222–7.

    Article  PubMed  Google Scholar 

  118. Craven A, Robson J, Ponte C, Grayson PC, Suppiah R, Judge A, et al. ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). Clin Exp Nephrol. 2013;17(5):619–21.

    Article  CAS  PubMed  Google Scholar 

  119. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 1990;33(8):1101–7.

    Article  CAS  PubMed  Google Scholar 

  120. Beasley MJ. Lymphoma of the thyroid and head and neck. Clin Oncol. 2012;24(5):345–51.

    Article  CAS  Google Scholar 

  121. Laudien M. Orphan diseases of the nose and paranasal sinuses: pathogenesis – clinic – therapy. GMS Curr Top Otorhinolaryngol Head Neck Surg 2015;14:Doc04.

    Google Scholar 

  122. Hsu YP, Chang PH, Lee TJ, Hung LY, Huang CC. Extranodal natural killer/T-cell lymphoma nasal type: detection by computed tomography features. Laryngoscope. 2014;124(12):2670–5.

    Article  PubMed  Google Scholar 

  123. Valent P, Gleich GJ, Reiter A, Roufosse F, Weller PF, Hellmann A, et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol. 2012;5(2):157–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Mouthon L, Dunogue B, Guillevin L. Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome). J Autoimmun. 2014;48-49:99–103.

    Article  CAS  PubMed  Google Scholar 

  125. Bachert C, van Steen K, Zhang N, Holtappels G, Cattaert T, Maus B, et al. Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma. J Allergy Clin Immunol. 2012;130(2):376–81.e8.

    Article  CAS  PubMed  Google Scholar 

  126. Miziara ID, Araujo Filho BC, La Cortina RC, Romano FR, Lima AS. Chronic rhinosinusitis in HIV-infected patients: radiological and clinical evaluation. Braz J Otorhinolaryngol. 2005;71(5):604–8.

    Article  PubMed  Google Scholar 

  127. Chee L, Graham SM, Carothers DG, Ballas ZK. Immune dysfunction in refractory sinusitis in a tertiary care setting. Laryngoscope. 2001;111(2):233–5.

    Article  CAS  PubMed  Google Scholar 

  128. Alqudah M, Graham SM, Ballas ZK. High prevalence of humoral immunodeficiency patients with refractory chronic rhinosinusitis. Am J Rhinol Allergy. 2010;24(6):409–12.

    Article  PubMed  Google Scholar 

  129. May A, Zielen S, von Ilberg C, Weber A. Immunoglobulin deficiency and determination of pneumococcal antibody titers in patients with therapy-refractory recurrent rhinosinusitis. Eur Arch Otorhinolaryngol. 1999;256(9):445–9.

    Article  CAS  PubMed  Google Scholar 

  130. Vanlerberghe L, Joniau S, Jorissen M. The prevalence of humoral immunodeficiency in refractory rhinosinusitis: a retrospective analysis. B-ENT. 2006;2(4):161–6.

    CAS  PubMed  Google Scholar 

  131. Schwitzguebel AJ, Jandus P, Lacroix JS, Seebach JD, Harr T. Immunoglobulin deficiency in patients with chronic rhinosinusitis: systematic review of the literature and meta-analysis. J Allergy Clin Immunol. 2015;136(6):1523–31.

    Article  PubMed  Google Scholar 

  132. Park MA, Li JT, Hagan JB, Maddox DE, Abraham RS. Common variable immunodeficiency: a new look at an old disease. Lancet. 2008;372(9637):489–502.

    Article  PubMed  Google Scholar 

  133. Quinti I, Soresina A, Spadaro G, Martino S, Donnanno S, Agostini C, et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol. 2007;27(3):308–16.

    Article  PubMed  Google Scholar 

  134. Wang KL, Nichols BG, Poetker DM, Loehrl TA. Odontogenic sinusitis: a case series studying diagnosis and management. Int Forum Allergy Rhinol. 2015;5(7):597–601.

    Article  PubMed  Google Scholar 

  135. Patel NA, Ferguson BJ. Odontogenic sinusitis: an ancient but under-appreciated cause of maxillary sinusitis. Curr Opin Otolaryngol Head Neck Surg. 2012;20(1):24–8.

    Article  PubMed  Google Scholar 

  136. Crovetto-Martinez R, Martin-Arregui FJ, Zabala-Lopez-de-Maturana A, Tudela-Cabello K, Crovetto-de la Torre MA. Frequency of the odontogenic maxillary sinusitis extended to the anterior ethmoid sinus and response to surgical treatment. Med Oral Patol Oral Cir Bucal. 2014;19(4):e409–13.

    Article  PubMed  PubMed Central  Google Scholar 

  137. Brook I. Sinusitis of odontogenic origin. Otolaryngol Head Neck Surg. 2006;135(3):349–55.

    Article  PubMed  Google Scholar 

  138. Chang EH. New insights into the pathogenesis of cystic fibrosis sinusitis. Int Forum Allergy Rhinol. 2014;4(2):132–7.

    Article  PubMed  Google Scholar 

  139. Barbato A, Frischer T, Kuehni CE, Snijders D, Azevedo I, Baktai G, et al. Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children. Eur Respir J. 2009;34(6):1264–76.

    Article  CAS  PubMed  Google Scholar 

  140. Marthin JK, Nielsen KG. Choice of nasal nitric oxide technique as first-line test for primary ciliary dyskinesia. Eur Respir J. 2011;37(3):559–65.

    Article  CAS  PubMed  Google Scholar 

  141. Mateos-Corral D, Coombs R, Grasemann H, Ratjen F, Dell SD. Diagnostic value of nasal nitric oxide measured with non-velum closure techniques for children with primary ciliary dyskinesia. J Pediatr. 2011;159(3):420–4.

    Article  CAS  PubMed  Google Scholar 

  142. Rank MA, Wollan P, Kita H, Yawn BP. Acute exacerbations of chronic rhinosinusitis occur in a distinct seasonal pattern. J Allergy Clin Immunol. 2010;126(1):168–9.

    Article  PubMed  PubMed Central  Google Scholar 

  143. Outzen KE, Grontveld A, Jorgensen K, Clausen PP, Ladefoged C. Inverted papilloma: incidence and late results of surgical treatment. Rhinology. 1996;34(2):114–8.

    CAS  PubMed  Google Scholar 

  144. Chang JE, White A, Simon RA, Stevenson DD. Aspirin-exacerbated respiratory disease: burden of disease. Allergy Asthma Proc. 2012;33(2):117–21.

    Article  CAS  PubMed  Google Scholar 

  145. Divekar R, Hagan J, Rank M, Park M, Volcheck G, O’Brien E, et al. Diagnostic utility of urinary LTE4 in asthma, allergic rhinitis, chronic rhinosinusitis, nasal polyps, and aspirin sensitivity. J Allergy Clin Immunol Pract. 2016;4(4):665–70.

    Article  PubMed  PubMed Central  Google Scholar 

  146. Laidlaw TM, Boyce JA. Platelets in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015;135(6):1407–14. quiz 15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. Kowalski ML, Ptasinska A, Jedrzejczak M, Bienkiewicz B, Cieslak M, Grzegorczyk J, et al. Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest). Allergy. 2005;60(9):1139–45.

    Article  CAS  PubMed  Google Scholar 

  148. Bent JP 3rd, Kuhn FA. Diagnosis of allergic fungal sinusitis. Otolaryngol Head Neck Surg. 1994;111(5):580–8.

    Article  PubMed  Google Scholar 

  149. deShazo RD, Swain RE. Diagnostic criteria for allergic fungal sinusitis. J Allergy Clin Immunol. 1995;96(1):24–35.

    Article  CAS  PubMed  Google Scholar 

  150. Wise SK, Rogers GA, Ghegan MD, Harvey RJ, Delgaudio JM, Schlosser RJ. Radiologic staging system for allergic fungal rhinosinusitis (AFRS). Otolaryngol Head Neck Surg. 2009;140(5):735–40.

    Article  PubMed  Google Scholar 

  151. Chen IH, Chen TM. Isolated frontal sinus aspergillosis. Otolaryngol Head Neck Surg. 2000;122(3):460–1.

    Article  CAS  PubMed  Google Scholar 

  152. Panda NK, Ekambar Eshwara Reddy C. Primary frontal sinus aspergillosis: an uncommon occurrence. Mycoses. 2005;48(4):235–7.

    Article  PubMed  Google Scholar 

  153. Gupta AK, Ghosh S. Sinonasal aspergillosis in immunocompetent Indian children: an eight-year experience. Mycoses. 2003;46(11–12):455–61.

    Article  CAS  PubMed  Google Scholar 

  154. Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009;124(6):1319–25.e3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  155. Soler ZM, Eckert MA, Storck K, Schlosser RJ. Cognitive function in chronic rhinosinusitis: a controlled clinical study. Int Forum Allergy Rhinol. 2015;5(11):1010–7.

    Article  PubMed  Google Scholar 

  156. Levy JM, Mace JC, DeConde AS, Steele TO, Smith TL. Improvements in psychological dysfunction after endoscopic sinus surgery for patients with chronic rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(9):906–13.

    Article  PubMed  PubMed Central  Google Scholar 

  157. El Rassi E, Mace JC, Steele TO, Alt JA, Smith TL. Improvements in sleep-related symptoms after endoscopic sinus surgery in patients with chronic rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(4):414–22.

    Article  PubMed  Google Scholar 

  158. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nolle B, et al. An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum. 2000;43(5):1021–32.

    Article  CAS  PubMed  Google Scholar 

  159. Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015;26(7):545–53.

    Article  PubMed  Google Scholar 

  160. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52(8):2461–9.

    Article  CAS  PubMed  Google Scholar 

  161. Langford CA, Monach PA, Specks U, Seo P, Cuthbertson D, McAlear CA, et al. An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener’s). Ann Rheum Dis. 2014;73(7):1376–9.

    Article  CAS  PubMed  Google Scholar 

  162. Azar L, Springer J, Langford CA, Hoffman GS. Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener’s): a retrospective single-center study. Arthritis Rheumatol. 2014;66(10):2862–70.

    Article  CAS  PubMed  Google Scholar 

  163. Hoffman GS. Immunosuppressive therapy is always required for the treatment of limited Wegener’s granulomatosis. Sarcoidosis Vasc Diffuse Lung Dis. 1996;13(3):249–52.

    CAS  PubMed  Google Scholar 

  164. Cartin-Ceba R, Golbin JM, Keogh KA, Peikert T, Sanchez-Menendez M, Ytterberg SR, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): ten-year experience at a single center. Arthritis Rheum. 2012;64(11):3770–8.

    Article  CAS  PubMed  Google Scholar 

  165. Stone JH, Tun W, Hellman DB. Treatment of non-life threatening Wegener’s granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol. 1999;26(5):1134–9.

    CAS  PubMed  Google Scholar 

  166. Metzler C, Miehle N, Manger K, Iking-Konert C, de Groot K, Hellmich B, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener’s granulomatosis. Rheumatology (Oxford). 2007;46(7):1087–91.

    Article  CAS  Google Scholar 

  167. Lally L, Lebovics RS, Huang WT, Spiera RF. Effectiveness of rituximab for the otolaryngologic manifestations of granulomatosis with polyangiitis (Wegener’s). Arthritis Care Res. 2014;66(9):1403–9.

    Article  CAS  Google Scholar 

  168. Harabuchi Y, Kishibe K, Tateyama K, Morita Y, Yoshida N, Kunimoto Y, et al. Clinical features and treatment outcomes of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV): a retrospective analysis of 235 patients from a nationwide survey in Japan. Mod Rheumatol. 2016:1–8.

    Google Scholar 

  169. Malm IJ, Mener DJ, Kim J, Seo P, Kim YJ. Otolaryngological progression of granulomatosis with polyangiitis after systemic treatment with rituximab. Otolaryngol Head Neck Surg. 2014;150(1):68–72.

    Article  PubMed  Google Scholar 

  170. Seo P, Specks U, Keogh KA. Efficacy of rituximab in limited Wegener’s granulomatosis with refractory granulomatous manifestations. J Rheumatol. 2008;35(10):2017–23.

    CAS  PubMed  Google Scholar 

  171. Wojciechowska J, Krajewski W, Krajewski P, Krecicki T. Granulomatosis with polyangiitis in otolaryngologist practice: a review of current knowledge. Clin Exp Otorhinolaryngol. 2016;9(1):8–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  172. Mueller A, Holl-Ulrich K, Feller AC, Gross WL, Lamprecht P. Immune phenomena in localized and generalized Wegener’s granulomatosis. Clin Exp Rheumatol. 2003;21(6 Suppl 32):S49–54.

    CAS  PubMed  Google Scholar 

  173. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66(5):605–17.

    Article  CAS  PubMed  Google Scholar 

  174. Pagnoux C, Stubbe M, Lifermann F, Decaux O, Pavic M, Berezne A, et al. Wegener’s granulomatosis strictly and persistently localized to one organ is rare: assessment of 16 patients from the French Vasculitis Study Group database. J Rheumatol. 2011;38(3):475–8.

    Article  PubMed  Google Scholar 

  175. Holle JU, Gross WL, Holl-Ulrich K, Ambrosch P, Noelle B, Both M, et al. Prospective long-term follow-up of patients with localised Wegener’s granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis. 2010;69(11):1934–9.

    Article  PubMed  Google Scholar 

  176. Goldfarb JM, Rabinowitz MR, Basnyat S, Nyquist GG, Rosen MR. Head and neck manifestations of eosinophilic granulomatosis with polyangiitis: a systematic review. Otolaryngol Head Neck Surg. 2016;155(5):771–8.

    Article  PubMed  Google Scholar 

  177. Gulati S, Krossnes B, Olofsson J, Danielsen A. Sinonasal involvement in sarcoidosis: a report of seven cases and review of literature. Eur Arch Otorhinolaryngol. 2012;269(3):891–6.

    Article  CAS  PubMed  Google Scholar 

  178. Knopf A, Lahmer T, Chaker A, Stark T, Hofauer B, Pickhard A, et al. Head and neck sarcoidosis, from wait and see to tumor necrosis factor alpha therapy: a pilot study. Head Neck. 2013;35(5):715–9.

    Article  PubMed  Google Scholar 

  179. Baughman RP, Lower EE. Treatment of sarcoidosis. Clin Rev Allergy Immunol. 2015;49(1):79–92.

    Article  CAS  PubMed  Google Scholar 

  180. Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 2015;67(7):1688–99.

    Article  CAS  PubMed  Google Scholar 

  181. Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171–7.

    Article  CAS  PubMed  Google Scholar 

  182. Orange JS, Belohradsky BH, Berger M, Borte M, Hagan J, Jolles S, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol. 2012;169(2):172–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  183. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137(1):21–30.

    Article  CAS  PubMed  Google Scholar 

  184. Liang J, Higgins T, Ishman SL, Boss EF, Benke JR, Lin SY. Medical management of chronic rhinosinusitis in cystic fibrosis: a systematic review. Laryngoscope. 2014;124(6):1308–13.

    Article  CAS  PubMed  Google Scholar 

  185. Chang EH, Tang XX, Shah VS, Launspach JL, Ernst SE, Hilkin B, et al. Medical reversal of chronic sinusitis in a cystic fibrosis patient with ivacaftor. Int Forum Allergy Rhinol. 2015;5(2):178–81.

    Article  PubMed  Google Scholar 

  186. Brook I. The role of anaerobic bacteria in sinusitis. Anaerobe. 2006;12(1):5–12.

    Article  CAS  PubMed  Google Scholar 

  187. Cincik H, Ferguson BJ. The impact of endoscopic cultures on care in rhinosinusitis. Laryngoscope. 2006;116(9):1562–8.

    Article  PubMed  Google Scholar 

  188. Casiano RR, Cohn S, Villasuso E 3rd, Brown M, Memari F, Barquist E, et al. Comparison of antral tap with endoscopically directed nasal culture. Laryngoscope. 2001;111(8):1333–7.

    Article  CAS  PubMed  Google Scholar 

  189. Gold SM, Tami TA. Role of middle meatus aspiration culture in the diagnosis of chronic sinusitis. Laryngoscope. 1997;107(12 Pt 1):1586–9.

    Article  CAS  PubMed  Google Scholar 

  190. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50(1):1–12.

    Article  PubMed  Google Scholar 

  191. Nadel DM, Lanza DC, Kennedy DW. Endoscopically guided cultures in chronic sinusitis. Am J Rhinol. 1998;12(4):233–41.

    Article  CAS  PubMed  Google Scholar 

  192. Bachert C, Akdis CA. Phenotypes and emerging endotypes of chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2016;4(4):621–8.

    Article  PubMed  Google Scholar 

  193. Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989–95. e1–8.

    Article  CAS  PubMed  Google Scholar 

  194. Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118(5):1133–41.

    Article  CAS  PubMed  Google Scholar 

  195. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469–79.

    Article  CAS  PubMed  Google Scholar 

  196. Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis. J Allergy Clin Immunol. 2015;136(6):1431–40. quiz 41

    Article  CAS  PubMed  Google Scholar 

  197. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110–6.e1.

    Article  CAS  PubMed  Google Scholar 

  198. Laidlaw TM, Boyce JA. Aspirin-exacerbated respiratory disease – new prime suspects. N Engl J Med. 2016;374(5):484–8.

    Article  CAS  PubMed  Google Scholar 

  199. Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy, Asthma Immunol Res. 2011;3(1):3–10.

    Article  CAS  Google Scholar 

  200. Simon RA, Dazy KM, Waldram JD. Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD). Curr Allergy Asthma Rep. 2015;15(3):508.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Drs. Rodrigo Cartin-Ceba and Devyani Lal, both from Mayo Clinic Arizona, for their input on this chapter.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Medicine, Mayo Clinic, Scottsdale, AZ, USA

    Lester E. Mertz

  2. Division of Allergic Diseases, Mayo Clinic, Rochester, MN, USA

    Rohit Divekar

  3. Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic, Scottsdale, AZ, USA

    Matthew A. Rank

Authors
  1. Lester E. Mertz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rohit Divekar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthew A. Rank
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Prof of Otolaryngology, Mayo Clinic College of Medicine and Science, Associate Dean, Mayo Clinic School of Continuous Professional Development, Consultant, Dept of Otolaryngology-Head and Neck Surgery, Consultant (Joint), Dept of Neurological Surgery, Mayo Clinic, Phoenix, AZ, USA

    Devyani Lal

  2. Professor and Chief, Division of Rhinology and Endoscopic Skull Base Surgery, Department of Otolaryngology – Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA

    Peter H. Hwang

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mertz, L.E., Divekar, R., Rank, M.A. (2019). Managing Frontal Sinusitis from Systemic Inflammatory Disease. In: Lal, D., Hwang, P. (eds) Frontal Sinus Surgery. Springer, Cham. https://doi.org/10.1007/978-3-319-97022-6_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-97022-6_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-97021-9

  • Online ISBN: 978-3-319-97022-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation